Primary resistance to first-generation EGFR-TKIs induced by MDM2 amplification in NSCLC

INTRODUCTION: Targeted therapy for NSCLC is rapidly evolving. EGFR-TKIs benefit NSCLC patients with sensitive EGFR mutations and significantly prolong survival. However, 20–30% of patients demonstrate primary resistance to EGFR-TKIs, which leads to the failure of EGFR-TKI treatment. The mechanisms o...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Dantong, Zhu, Yan, Zhu, Jingjuan, Tao, Junyan, Wei, Xiaojuan, Wo, Yang, Hou, Helei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7329552/
https://www.ncbi.nlm.nih.gov/pubmed/32611363
http://dx.doi.org/10.1186/s10020-020-00193-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7329552/
https://www.ncbi.nlm.nih.gov/pubmed/32611363
http://dx.doi.org/10.1186/s10020-020-00193-z

Ejemplares similares